Patient Square Capital LP Has $8.62 Million Stock Position in Pharvaris N.V. $PHVS

Patient Square Capital LP boosted its position in Pharvaris N.V. (NASDAQ:PHVS) by 41.4% during the third quarter, HoldingsChannel.com reports. The fund owned 345,381 shares of the company’s stock after buying an additional 101,098 shares during the quarter. Pharvaris makes up 2.3% of Patient Square Capital LP’s portfolio, making the stock its 8th biggest position. Patient Square Capital LP’s holdings in Pharvaris were worth $8,617,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in the company. BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new stake in Pharvaris during the second quarter worth $57,000. JPMorgan Chase & Co. lifted its position in shares of Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after buying an additional 783 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in Pharvaris in the third quarter valued at about $75,000. Legal & General Group Plc boosted its stake in Pharvaris by 17.2% in the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock valued at $203,000 after buying an additional 1,695 shares in the last quarter. Finally, California State Teachers Retirement System grew its position in Pharvaris by 9.8% in the second quarter. California State Teachers Retirement System now owns 14,048 shares of the company’s stock valued at $247,000 after acquiring an additional 1,257 shares during the last quarter.

Analyst Ratings Changes

A number of research firms have recently commented on PHVS. Leerink Partners set a $38.00 target price on shares of Pharvaris in a report on Wednesday, December 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a research note on Thursday, January 22nd. Citigroup restated a “market outperform” rating on shares of Pharvaris in a research report on Wednesday, November 19th. Wall Street Zen upgraded shares of Pharvaris from a “sell” rating to a “hold” rating in a report on Saturday, February 7th. Finally, Wedbush increased their price target on Pharvaris from $27.00 to $30.00 and gave the company an “outperform” rating in a research note on Thursday, November 13th. Nine investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Pharvaris has an average rating of “Moderate Buy” and an average price target of $40.56.

Pharvaris Trading Up 0.4%

NASDAQ:PHVS opened at $28.10 on Monday. Pharvaris N.V. has a one year low of $11.51 and a one year high of $29.80. The firm’s 50 day simple moving average is $26.34 and its 200 day simple moving average is $24.50.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.